Table 1.
Patient characteristics
| Parameters | Total (n = 132) | No DBF (n = 72) | DBF (n = 60) |
|---|---|---|---|
| Sex (male %) | 75 (56.8%) | 47 (65.3%) | 28 (46.7%) |
| Age (years) | 57 (27-87) | 58 (38-80) | 57 (27-87) |
| No. of metastases | 1 (1-6) | 1 (1-4) | 2 (1-6) |
| 1 | 86 (65.2%) | 57 (43.2%) | 29 (22.0%) |
| > 1 | 46 (34.8%) | 15 (11.4%) | 31 (23.5%) |
| Total target volume (cc) | 4.26 (0.10-57.84) | 3.42 (0.23-57.84) | 3.45 (0.10-45.47) |
| > 6 | 50 (37.9%) | 22 (16.7%) | 28 (21.2%) |
| ≤ 6 | 82 (62.1%) | 50 (37.9%) | 32 (24.2%) |
| Extracranial disease | |||
| Progressive | 91 (68.9%) | 43 (32.6%) | 48 (36.4%) |
| Absent or controlled | 41 (31.1%) | 29 (22.0%) | 12 (9.1%) |
| IT (months) | 12 (0-240) | 12 (0-240) | 13 (0-192) |
| ≥ 60 | 20 (15.2%) | 15 (11.4%) | 5 (3.8%) |
| < 60 | 112 (84.8%) | 57 (43.2%) | 55 (41.7%) |
| KPS score | 80 (40-90) | 80 (40-90) | 70 (50-90) |
| KPS = 70 | 45 (34.1%) | 18 (13.6%) | 27 (20.5%) |
| KPS ≠ 70 | 87 (65.9%) | 54 (40.9%) | 33 (25.0%) |
| Histologic characteristics | |||
| NSCLC | 79 (59.8%) | 45 (34.1%) | 34 (25.8%) |
| Melanoma | 5 (3.8%) | 2 (1.5%) | 3 (2.3%) |
| Breast cancer | 15 (11.4%) | 8 (6.1%) | 7 (5.3%) |
| RCC | 9 (6.8%) | 6 (4.5%) | 3 (2.3%) |
| Other | 24 (18.2%) | 11 (8.3%) | 13 (9.8%) |
IT, interval time; KPS, Karnofsky performance score; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma